Dergiler / Gülhane Tıp Dergisi / 2020 / Cilt: 62 - Sayı: 4

The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome

Sayfa
272–277
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

ESSDAI was not correlated with C3 (r=0.044, p=0.697), C4 (r=-0.053, p=0.640), ESR (r=0.111, p=0.326), CRP (r=0.111, p=0.324) and IgG (r=0.154, p=0.169).Conclusions: Although serum B2M levels were higher in autoantibody positive patients, it has a weak correlation with clinical disease activity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: The aim of the this study is to evaluate beta-2-microglobulin (B2M) levels in patients with primary Sjögren’s syndrome (pSS) and to investigate their correlation with serum biomarkers and disease activity indexes commonly used in daily clinical practice.Methods: Eighty-one patients with pSS were included in this retrospective and cross-sectional study.
📊
Temel Bulgular & Veri:Demographic data, clinical characteristics, B2M, immunoglobulin (Ig) A, IgG, IgM, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum complement (C) 3 and C4 levels, anti-nuclear antibody, rheumatoid factor (RF), anti-SSA and anti-SSB antibodies were obtained from the medical records.
💡
Sonuç & Katkı:ESSDAI was not correlated with C3 (r=0.044, p=0.697), C4 (r=-0.053, p=0.640), ESR (r=0.111, p=0.326), CRP (r=0.111, p=0.324) and IgG (r=0.154, p=0.169).Conclusions: Although serum B2M levels were higher in autoantibody positive patients, it has a weak correlation with clinical disease activity.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aims: The aim of the this study is to evaluate beta-2-microglobulin (B2M) levels in patients with primary Sjögren’s syndrome (pSS) and to investigate their correlation with serum biomarkers and disease activity indexes commonly used in daily clinical practice.Methods: Eighty-one patients with pSS were included in this retrospective and cross-sectional study. Demographic data, clinical characteristics, B2M, immunoglobulin (Ig) A, IgG, IgM, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum complement (C) 3 and C4 levels, anti-nuclear antibody, rheumatoid factor (RF), anti-SSA and anti-SSB antibodies were obtained from the medical records. Disease activity was evaluated by the European League Against Rheumatism (EULAR) SS Disease Activity Index (ESSDAI) and EULAR SS Patients Reported Index (ESSPRI). Results: Serum B2M level was significantly higher in patients with anti-SSA and anti-SSB antibody (median: 2.64 mg/dL, minimum: 2.02 mg/dL, maximum: 10.10 mg/dL) than in only anti-SSA positive patients (median: 2.31 mg/dL, minimum: 1.33 mg/dL, maximum: 4.26 mg/dL, p=0.010) and both antibody negative patients (median: 1.80 mg/dL, minimum: 1.20 mg/dL, maximum: 2.65 mg/dL, p<0.001). Also, patients with anti-SSA antibody have significantly higher serum B2M levels than anti-SSA and anti-SSB antibodies negative patients (p=0.009). Serum B2M level was significantly correlated with ESSDAI (r=0.482, p=0.001), serum IgG level (r=0.374, p=0.001), IgA level (r=0.341, p=0.002), RF levels (r=0.412, p=0.021) and ESR (r=0.239, p:0.031). There was no correlation between ESSPRI, IgM, CRP and serum B2M levels. ESSDAI was not correlated with C3 (r=0.044, p=0.697), C4 (r=-0.053, p=0.640), ESR (r=0.111, p=0.326), CRP (r=0.111, p=0.324) and IgG (r=0.154, p=0.169).Conclusions: Although serum B2M levels were higher in autoantibody positive patients, it has a weak correlation with clinical disease activity.

🔖

Bu Makaleye Atıf Yap

TECER, D., BÜYÜKŞİRECİ, D. E., GÜNENDİ, Z., GÖGÜŞ, F. (2020). The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. Gülhane Tıp Dergisi, Cilt: 62 - Sayı: 4, 272–277. https://ajindex.com/articles/226067

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Ferro F, Marcucci E, Orlandi M, Baldini C, Bartoloni-Bocci E. One year in review 2017: primary Sjogren’s syndrome. Clin Exp Rheumatol. 2017;35:179-191
  2. Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321-331
  3. Barone F, Colafrancesco S. Sjogren’s syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol. 2016;34(Suppl 4):58-62
  4. Goules AV, Tzioufas AG. Primary Sjogren’s syndrome: clinical phenotypes, outcome and the development of biomarkers. Immunol Res. 2017;65:331-344
  5. Brito-Zeron P, Theander E, Baldini C, et al. Early diagnosis of primary Sjogren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12:137-156
  6. Chiou SJ, Chen CH. Decipher beta2-microglobulin: gainor loss-of-function (a mini-review). Med Sci Monit Basic Res. 2013;19:271-273
  7. Argyropoulos CP, Chen SS, Ng YH, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Front Med (Lausanne). 2017;4:73
  8. Yeung CK, Wong KL, Wong WS, Chan KH. Beta 2-microglobulin and systemic lupus erythematosus. J Rheumatol. 1986;13:1053-1058
  9. Yang J, Qian J, Wezeman M, et al. Targeting beta2- microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10:295- 307
  10. Yilmaz B, Koklu S, Yuksel O, Arslan S. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol. 2014;20:10916-10920
  11. Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis. 1999;58:423-427
  12. Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjogren’s syndrome: A study of 78 patients. Rheumatology (Oxford). 1999;38:1113-1120
  13. Pertovaara M, Korpela M, Pasternack A. Factors predictive of renal involvement in patients with primary Sjogren’s syndrome. Clin Nephrol. 2001;56:10-18
  14. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001;60:467-472
  15. Pertovaara M, Korpela M, Saarelainen S, et al. Longterm follow-up study of pulmonary findings in patients with primary Sjogren’s syndrome. Scand J Rheumatol. 2004;33:343-348
  16. Michalski JP, Daniels TE, Talal N, Grey HM. Beta2 microglobulin and lymphocytic infiltration in Sjogren’s syndrome. N En